Satellite Banner
Technology Networks Header
Tuesday, September 23, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Nanobiotix Presents Successful Phase I Results for NBTXR3 at ASCO
Tuesday, June 03, 2014
Final results demonstrate a very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas.

Multiplicom Launches Two New Diagnostic Kits
Tuesday, June 03, 2014
Company aims for strong growth in the rapidly expanding molecular diagnostic market.

OGT to Sell Cytocell Products Direct in North America
Monday, June 02, 2014
The acquisition brings immediate customer benefits.

Nodality Announces Publication of Promising Data in Melanoma in JTM
Friday, May 30, 2014
Nodality's SCNP platform holds strong potential in aiding the development of new cancer and immuno-oncology treatments.

New Cancer Diagnostic Device
Thursday, May 29, 2014
Commercial launch of a new system to improve cancer diagnosis and treatment.

Debiopharm Moves Forward Three of its Oncology Clinical Programs
Thursday, May 29, 2014
Company will present the recent progresses at the 50th American Society of Clinical Oncology Annual Meeting.

Extraordinary Tools for Exceptional Results
Wednesday, May 28, 2014
New Rainin Pipet-Lite™ XLS+™ manual pipettes from Anachem.

Powerful Tool for Genomic Editing
Friday, May 23, 2014
CRISPR/Cas9 - Designed to produce a genetically modified cell.

New 20µl Liquidator 96 from Anachem
Thursday, May 22, 2014
Maximizes users workflow with fast, 96-well pipetting and no complex programming.

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 2519
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv